πŸ‡ΊπŸ‡Έ FDA
Patent

US 9358285

Granulysin in immunotherapy

granted A61KA61K2039/55516A61K2039/55522

Quick answer

US patent 9358285 (Granulysin in immunotherapy) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2039/55516, A61K2039/55522, A61K2039/55527, A61K2239/57